ATE440861T1 - Immunisierung gegen chlamydia pneumoniae - Google Patents

Immunisierung gegen chlamydia pneumoniae

Info

Publication number
ATE440861T1
ATE440861T1 AT01954278T AT01954278T ATE440861T1 AT E440861 T1 ATE440861 T1 AT E440861T1 AT 01954278 T AT01954278 T AT 01954278T AT 01954278 T AT01954278 T AT 01954278T AT E440861 T1 ATE440861 T1 AT E440861T1
Authority
AT
Austria
Prior art keywords
chlamydia pneumoniae
immunization against
against chlamydia
pneumoniae
immunisation
Prior art date
Application number
AT01954278T
Other languages
English (en)
Inventor
Giulio Ratti
Guido Grandi
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016363A external-priority patent/GB0016363D0/en
Priority claimed from GB0017047A external-priority patent/GB0017047D0/en
Priority claimed from GB0017983A external-priority patent/GB0017983D0/en
Priority claimed from GB0019368A external-priority patent/GB0019368D0/en
Priority claimed from GB0020440A external-priority patent/GB0020440D0/en
Priority claimed from GB0022583A external-priority patent/GB0022583D0/en
Priority claimed from GB0027549A external-priority patent/GB0027549D0/en
Priority claimed from GB0031706A external-priority patent/GB0031706D0/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE440861T1 publication Critical patent/ATE440861T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01954278T 2000-07-03 2001-07-03 Immunisierung gegen chlamydia pneumoniae ATE440861T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0016363A GB0016363D0 (en) 2000-07-03 2000-07-03 Immunisation against chlamydia pneumoniae
GB0017047A GB0017047D0 (en) 2000-07-11 2000-07-11 Immunisation against chlamydia pneumoniae
GB0017983A GB0017983D0 (en) 2000-07-21 2000-07-21 Immunisation against chlamydia pneumoniae
GB0019368A GB0019368D0 (en) 2000-08-07 2000-08-07 Immunisation against chlamydia pneumoniae
GB0020440A GB0020440D0 (en) 2000-08-18 2000-08-18 Immunisation against chlamydia pneumoniae
GB0022583A GB0022583D0 (en) 2000-09-14 2000-09-14 Immunisation against chlamydia pneumoniae
GB0027549A GB0027549D0 (en) 2000-11-10 2000-11-10 Immunisation against chlamydia pneumoniae
GB0031706A GB0031706D0 (en) 2000-12-22 2000-12-22 Immunisation against chlamydia pneumoniae
PCT/IB2001/001445 WO2002002606A2 (en) 2000-07-03 2001-07-03 Immunisation against chlamydia pneumoniae

Publications (1)

Publication Number Publication Date
ATE440861T1 true ATE440861T1 (de) 2009-09-15

Family

ID=27571146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01954278T ATE440861T1 (de) 2000-07-03 2001-07-03 Immunisierung gegen chlamydia pneumoniae

Country Status (8)

Country Link
US (4) US20040005667A1 (de)
EP (2) EP2166019A3 (de)
JP (2) JP2004502415A (de)
AT (1) ATE440861T1 (de)
AU (1) AU2001276619A1 (de)
CA (1) CA2414884A1 (de)
DE (1) DE60139690D1 (de)
WO (1) WO2002002606A2 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
ATE229978T1 (de) * 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
DK0909323T3 (da) * 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
WO2000011180A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING POMP91A PROTEIN OF $i(CHLAMYDIA)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1135501A1 (de) 1998-12-01 2001-09-26 Aventis Pasteur Limited Chlamydia antigene, dafür kodierende dna und deren verwendung
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU774902B2 (en) 1998-12-28 2004-07-15 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP2172214A3 (de) 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia-Antigene und entsprechende DNA-Fragmente sowie Verwendungen davon
JP4695763B2 (ja) 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
EP1220925B8 (de) 1999-09-20 2008-04-23 Sanofi Pasteur Limited Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
NZ520200A (en) * 1999-12-22 2004-04-30 Aventis Pasteur Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20050175629A1 (en) * 2001-08-31 2005-08-11 Giuseppe Del Giudice Helicobacter pylori vaccination
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK1556477T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
WO2005017308A1 (en) * 2003-08-19 2005-02-24 Shell Internationale Research Maatschappij B.V. Drilling system and method
CN1906299A (zh) * 2003-11-21 2007-01-31 圣诺菲·帕斯图尔有限公司 抗衣原体感染的免疫接种
BRPI0508365A (pt) * 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US20070259445A1 (en) * 2006-05-05 2007-11-08 Blas Cerda Quantitative analysis of surface-derived samples using mass spectrometry
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
EA018068B1 (ru) 2008-03-03 2013-05-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности tlr
US20110236489A1 (en) 2008-09-18 2011-09-29 Novartis Ag Vaccine adjuvant combinations
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
MX345967B (es) 2009-10-30 2017-02-28 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
EP2558596B1 (de) * 2010-04-16 2018-03-14 The Government Of The United States Of America As Reresented By The Secretary Of The Department Of Health & Human Services Echtzeit-pcr-test zum nachweis von bakteriellen erregern von atemwegserkrankungen
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
CN103313725B (zh) 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
EP3520813B1 (de) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigenfreisetzungsplattformen
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
AU2012255266B2 (en) 2011-05-17 2017-05-25 California Institute Of Technology Human immunodeficiency virus neutralizing antibodies and methods of use thereof
BR112013032410A2 (pt) * 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
EP3854413A1 (de) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
LT2822947T (lt) 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Tlr7 agonisto arginino druskos
EP2822586A1 (de) 2012-03-07 2015-01-14 Novartis AG Adjuvierte formulierungen von streptococcus pneumoniae-antigenen
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2852414B9 (de) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningokokken-serogruppe-x-konjugat
EP4056198A3 (de) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Aussenmembranvesikel
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
EP3623361B1 (de) 2013-12-19 2021-08-18 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3061826A1 (de) 2015-02-27 2016-08-31 Novartis AG Flavivirus-replikons
EP4218805A1 (de) 2015-07-21 2023-08-02 ModernaTX, Inc. Impfstoffe gegen infektionskrankheiten
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364950A4 (de) 2015-10-22 2019-10-23 ModernaTX, Inc. Impfstoffe gegen tropenkrankheiten
AU2016354444B2 (en) * 2015-11-10 2021-04-01 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
EP4229208A4 (de) 2020-10-14 2024-10-30 George Mason Research Foundation, Inc. Verfahren zur herstellung von lipidnanopartikeln und zusammensetzungen daraus
EP4240843A1 (de) 2020-11-04 2023-09-13 Eligo Bioscience Rekombinante phagen von cutibacterium acnes, herstellungsverfahren und verwendungen davon
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2026033498A1 (en) 2024-08-09 2026-02-12 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
EP1007685B1 (de) * 1997-06-23 2006-04-12 Loke Diagnostics ApS Oberfläche-exponierte proteine von chlamydia pneumoniae
ES2278420T3 (es) * 1997-11-21 2007-08-01 Serono Genetics Institute S.A. Secuencia genomica y polipeptidos de chlamydia pneumoniae, fragmentos de los mismos y uso de los mismos, en particular para diagnostico, prevencion y tratamiento de infeccion.
PT1032674E (pt) * 1997-11-21 2007-03-30 Serono Genetics Inst Sa Sequência genómica e polipéptidos (de chlamydia pneumoniae), seus fragmentos e suas utilizações, em particular para o diagnóstico, prevenção e tratamento de infacção
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
TR200102500T2 (tr) * 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
JP4695763B2 (ja) 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
EP1220925B8 (de) 1999-09-20 2008-04-23 Sanofi Pasteur Limited Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
NZ520200A (en) 1999-12-22 2004-04-30 Aventis Pasteur Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae

Also Published As

Publication number Publication date
DE60139690D1 (de) 2009-10-08
EP2166019A2 (de) 2010-03-24
JP2004502415A (ja) 2004-01-29
JP2012147798A (ja) 2012-08-09
EP2166019A3 (de) 2010-06-09
AU2001276619A1 (en) 2002-01-14
CA2414884A1 (en) 2002-01-10
EP1297005A2 (de) 2003-04-02
US20100056447A1 (en) 2010-03-04
WO2002002606A2 (en) 2002-01-10
US20120171236A1 (en) 2012-07-05
US20040005667A1 (en) 2004-01-08
WO2002002606A3 (en) 2002-06-06
US20070116726A1 (en) 2007-05-24
EP1297005B1 (de) 2009-08-26

Similar Documents

Publication Publication Date Title
DE60139690D1 (de) Immunisierung gegen chlamydia pneumoniae
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
NO976119D0 (no) OMP26-antigen fra Haemophilus influenzae
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
ATE411043T1 (de) Verfahren von dna-impfung
EP1935991A3 (de) Nukleinsäure-Impfstoffe zur Vorbeugung gegen Flavivirusinfektionen
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
ATE210296T1 (de) Immunologisches nachweisverfahren von antikörpern,die gegen gewebe-transglutaminase (ttg) gerichtet sind, verwendung von ttg zur diagnose und therapiekontrolle sowie orales pharmazeutisches mittel enthaltend ttg
WO2000022430A3 (en) Neisseria genomic sequences and methods of their use
ATE120487T1 (de) Therapeutische zusammensetzungen gegen streptokokken-infektionen, transformierte wirte, verfahren zur immunisierung und gentechnologisch hergestellte produkte.
DE60120621D1 (de) Lawsonia intracellularis Impfstoff
ITFI920052A1 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
AR003124A1 (es) Proteinas estreptococicas de shock termico miembros de la familia de hsp7270,secuencia de adn que codifica para dichos polipeptidos, vector deexpresion, molecula de adn recombinante, metodo para producir un polipeptido o fragmento del mismo, anticuerpo o fragmento del mismo y anticuerpo monoclonal,
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407
WO2002090504A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
TW200502402A (en) Escape mutants of newcastle disease virus as marker vaccines
Kunkle Molecular cloning and characterization of a unique 21-kilodalton antigen of Serpulina hyodysenteriae.
WO2002072771A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
TH44467A (th) วัคซีนแคมไพโลแบคเตอร์
NO941458L (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties